食管癌放化療面臨的挑戰(zhàn)與對策-文庫吧
2025-12-06 18:59 本頁面
【正文】 hieved in 92% of patients in the chemoradiotherapy–surgery group versus 69% inthe surgery group (P) ? A pathological plete response was achieved in 47 of 161 patients (29%) who underwent resection after chemoradiotherapy CROSS研究 N Engl J Med 2022。366:207484. 16 Quantifying the benefit of pathologic plete response after neoadjuvant chemoradiotherapyin the treatment of esophageal cancer ? 薈萃分析了 2 2篇文獻研究結(jié)果，進展期術前行新輔助放化療 ? 結(jié)果： pCR者 3年總生存為 ％， 5年總生存率為 ％ ； ? 未達 pCR者 5年生存率分別為 ％和 ％ ( P ) 。 ? 研究結(jié)論：綜合多項研究結(jié)果發(fā)現(xiàn)行術前放化療治療進展期食管癌，術后達 pCR患者 5總生存率均明顯提高。因此，行術前新輔助放化療治療進展期食管癌，評價術后 pCR對判 斷患者預后有重要的意義 。 Scheer R,et al. Int J Radiat Oncol Biol Phys， 2022， 80 (4) ： 9961001 17 同步放化療后達 PETCR者手術和非手術預后相似 18 Annals of Oncology 24: 1262–1266, 2022 Association between clinical plete response and pathological plete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort M. D. Anderson Cancer Center, Houston, USA Background: clinCR 定義為術前同步放化療后手術前內(nèi)鏡陰性 +PET陰性 pathCR 術后病理陰性 Results: 284 patients, 218 (77%) achieved clinCR. 67 (31%) of the 218 achieved pathCR. The sensitivity of clinCR for pathCR was % (67/69), The specificity was low (%。 64/215). Of the 66 patients who had less than a clinCR, only 2 (3%) had a pathCR. Thus, the rate of pathCR was significantly different in patients with clinCR than in those with less than a clinCR (P ). 19 ? 術前同步放化療后達 PCR患者治療前分子特征是什么 ? 基礎研究能否找到標記 20 二、放療最佳劑量
教學課件相關推薦
鄂ICP備17016276號-1